orladeyo
orladeyo: developed by 1 company · 2 FDA decisions. Updated within the last hour.
Development Pipeline (1)
| Company | Phase |
|---|---|
| BIOCRYST PHARMACEUTICALS INC (BCRX) | Approved |
FDA Decisions
Frequently asked questions
Who is developing orladeyo?
orladeyo is being developed by BIOCRYST PHARMACEUTICALS INC.
What is orladeyo's latest FDA decision?
The most recent tracked FDA decision for orladeyo is Approval for 1 INDICATIONS AND USAGE ORLADEYO ® is indicated for prophylaxis to prevent attacks of hereditary angioedema (HAE) in adults and pediatric patients 2 years of age and older. ORLADEYO is a plasma kallikrein inhibitor indicated for prophylaxis to prevent attacks of hereditary angioedema (HAE) in adults and pediatric patients 2 years and older. ( 1 ) Limitations of Use : ORLADEYO should not be used for treatment of acute HAE attacks. ( 1 ) Limitations of Use : The safety and effectiveness of ORLADEY, dated December 11, 2025.
Get deeper analysis on orladeyo
Full trial data, mechanism of action, competitive landscape, and AI-powered insights.
Start Free Analysis